Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn has submitted an abbreviated new drug application with the Office of Generic Drugs on behalf of Serum Institute of India.
Subscribe to our email newsletter
The submitted ANDA is a drug product that is given as a treatment for many different types of cancer, and Akorn expects to launch the drug product in 2010. Akorn and Serum Institute of India (SII) have signed an exclusive drug development and distribution agreement for 16 anti-cancer injectable products in October 2004.
Arthur Przybyl, president and CEO of Akorn, said: “This drug application represents the initial expansion of our product pipeline into anti-cancer injectables. Our partnership with Serum also includes development projects for four vaccine products and a rabies monoclonal antibody.”